Abstract
Background
The ONTARGET and TRANSCEND clinical trials were designed to investigate the cardioprotective effects of telmisartan 80 mg and ramipril 10 mg, alone and in combination, in patients at high risk of cardiovascular disease. Cardiac MRI enables investigation of mechanistic effects of these agents on cardiac structural and functional variables. Here, we report the design, analysis protocol, reproducibility and relevant quality control procedures, and baseline patient characteristics of the ONTARGET/TRANSCEND cardiac MRI substudy. MRI was undertaken in 330 subjects enrolled in ONTARGET, and 38 subjects in TRANSCEND, across eight centers in six countries. Analyses were performed by two independent analysts using guide-point modeling. Cases with discrepancies in LV mass (LVM) of >5% were independently reanalyzed. Cases with discrepancies in end-diastolic volume (EDV) of >5%, or end-systolic volume (ESV) of >12%, were then reconciled by consensus.
Results
Baseline characteristics were broadly similar to the main ONTARGET/TRANSCEND trials, except for a higher frequency of coronary artery disease and Asian ethnicity in the substudy. Reproducibility of MRI analyses (mean ± SD) were 2.8 ± 3.7 ml in EDV, −0.3 ± 3.6 ml in ESV, 3.1 ± 3.3 ml in SV, 1.1 ± 1.8% in EF, and 0.4 ± 4.5 g in LVM. Subgroup analyses revealed increased ESV and LVM, and reduced EF, in subjects with a history of either coronary artery disease or myocardial infarction.
Conclusions
The ONTARGET/TRANSCEND cardiac MRI substudy protocol provides for a reliable assessment of the effects of telmisartan and ramipril, alone and in combination, on cardiac structural and functional parameters over a 2-year follow-up period.
Similar content being viewed by others
References
Reddy K, Yusuf S (1998) Emerging epidemic of cardiovascular disease in developing countries. Circulation 97:596–601
Levy D, Garrison R, Savage D, Kannel W, Castelli W (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322:1561–1566
White H, Norris R, Brown M, Brandt P, Whitlock R, Wild C (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76:44–51
Devereux RB, Alderman MH (1993) Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88:1444–1455
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345–352
Levy D, Murabito JM, Anderson KM, Christiansen JC, Castelli WP (1994) Echocardiographic left ventricular hypertrophy: clinical characteristics: the Framingham heart study. Clin Exp Hypertens Part A Theory Pract 14:85–97
Bikkina M, Levy D, Evans JC, Larson MG, Benjamin EJ, Wolf PA et al (1994) Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 272:33–36
Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS (1992) The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 117:831–836
Bolognese L, Dellavesa P, Rossi L, Sarasso G, Bongo AS, Scianaro MC (1994) Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol 73:1–5
Laufer E, Jennings GL, Korner PI, Dewar E (1989) Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension. Hypertension 13:151–162
Muiesan ML, Salvetti M, Rizzoni D, Castellan M, Donato F, Agabiti-Rosei E (1995) Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13:1091–1095
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al (1998) Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 97:48–54
Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlof B (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292:2350–2356
Gosse P, Dubourg O, Gueret P (2003) Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. J Hypertens 21:217–221
Klingbeil AU, Schneider MP, Martus P, Messereli FH, Schmieder RE (2001) Treatment of left ventricular hypertrophy: meta-analysis of all randomised double-blind studies until 2000 (abstract). J Am Soc Nephrol 12:485A
Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al (2003) Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation 108:684–690
The ONTARGET Investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. New Engl J Med 358:1547–1559
The TRANSCEND Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 372:1174–1183
The HOPE Study Investigators (2000) Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on CV events in high-risk patients. N Engl J Med 342:145–153
Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, Magi A, Yusuf S (2004) Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. A substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 43:2200–2206
Anderson C (2005) Rationale and design of the cardiac magnetic resonance imaging substudy of the ONTARGET trial programme. J Int Med Res 33(Suppl 1):50A–57A
Pattynama P, De Roos A, Van der Wall E, Van Voorthuisen A (1994) Evaluation of cardiac function with magnetic resonance imaging. Am Heart J 128:595–607
Myerson SG, Bellenger NG, Pennell DJ (2002) Assessment of left ventricular mass by cardiovascular magnetic resonance. Hypertension 39:750–755
Bottini P, Carr A, Prisant L, Flickinger F, Allison J, Gottdiener J (1995) Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 8:221–228
Pattynama PMT, Lamb HJ, van der Velde EA, van der Wall EE, de Roos A (1993) Left ventricular measurements with cine and spin-echo MR imaging: a study of reproducibility with variance component analysis. Radiology 187:261–268
Reichek N (1991) Magnetic resonance imaging for assessment of myocardial function. Magn Reson Q 7:255–274
Fieno D, Jaffe W, Simonetti O, Judd R, Finn J (2002) TrueFISP: assessment of accuracy for measurement of left ventricular mass in an animal model. J Mag Reson Imaging 15:526–531
Weaver AN, Jones HU, Jelaco GK, Cha JA, Hall J, Walker K, Blatter DD, Anderson JL (2006) Magnitude and causes of interobserver discrepancies in CMR volume measurements: critical importance of choice of the basal slice. J Cardiovasc Magn Reson 8:82–83
Bloomer TN, Plein S, Radjenovic A, Higgins DM, Jones TR, Ridgway JP, Sivananthan MU (2001) Cine MRI using steady state free precession in the radial long axis orientation is a fast accurate method for obtaining volumetric data of the left ventricle. J Magn Reson Imaging 14:685–692
Young A, Cowan B, Thrupp S, Hedley W, Dell’Italia L (2000) Left ventricular mass and volume: Fast calculation with guide-point modeling on MR images. Radiology 216:597–602
Rodriguez I, Ennis DB, Wen H (2006) Noninvasive measurement of myocardial tissue volume change during systolic contraction and diastolic relaxation in the canine left ventricle. Magn Reson Med 55:484–490
Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein HU, Pennell DJ (2002) Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 90:29–34
Stewart RA, Gabriel R, Raffel OC, Cowan BR, Young AA, Whalley G, Occleshaw C, Zeng I, Kerr A (2007) Influence of beta-blockade on mitral regurgitant volume in patients with degenerative mitral valve prolapse. Circulation 116:II_680
Schmieder RE, Schlaich MP, Klingbeil AU, Martus P (1998) Update on reversal of left ventricular hypertrophy in essential hypertension (a meta analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13:564–569
Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al (2001) Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 104:1248–1254
Galzerano D, Tammaro P, del Viscovo L, Lama D, Galzerano A, Breglio R, Tuccillo B, Paolisso G, Capogrosso P (2005) Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 18:1563–1569
Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S (2007) Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951–958
Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M (2008) RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97(4):244–252
Clay S, Alfakih K, Messroghli DR, Jones T, Ridgway JP, Sivananthan MU (2006) The reproducibility of left ventricular volume and mass measurements: a comparison between dual-inversion-recovery black-blood sequence and SSFP. Eur Radiol 16:32–37
Steen H, Nasir K, Flynn E, El-Shehaby I, Lai S, Katus HA, Bluemcke D, Lima JA (2007) Is magnetic resonance imaging the ‘reference standard’ for cardiac functional assessment? Factors influencing measurement of left ventricular mass and volumes. Clin Res Cardiol 96(10):743–751
Lorenz C, Walker E, Morgan V, Klein S, Graham T (1999) Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. J Cardiovasc Magn Reson 1:7–21
Sievers B, Kirchberg S, Bakan A, Franken U, Trappe H-J (2004) Impact of papillary muscles in ventricular volume and ejection fraction assessment by cardiovascular magnetic resonance. J Cardiovasc MR 6:9–16
Stewart GA, Foster J, Cowan M, Rooney E, McDonagh T, Dargie HJ, Rodger RS, Jardine AG (1999) Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 56:2248–2253
Tseng W, Liao T, Wang J (2002) Normal systolic and diastolic functions of the left ventricle and left atrium by cine magnetic resonance imaging. J Cardiovasc Magn Reson 4:443–457
Acknowledgments
The authors thank Dr RA Stewart, Green Lane Cardiovascular Service, Auckland, New Zealand, for the inclusion of the scan-rescan reproducibility data.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the ONTARGET Investigators.
Rights and permissions
About this article
Cite this article
Cowan, B.R., Young, A.A., Anderson, C. et al. The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clin Res Cardiol 98, 421–433 (2009). https://doi.org/10.1007/s00392-009-0014-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-009-0014-4